Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study

David S. Alberts, Nancy L. Mason, Robert V. O'Toole, Robert D. Hilgers, Saul E. Rivkin, John G. Boutselis, Reginald P. Pugh, Vainutis K. Vaitkevicius, J. Benjamin Green, Noburu Oishi

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

A combination of doxorubicin (30 mg/m2 iv), cisplatin (50 mg/m2 iv), and vinblastine (5 mg/m2 iv) repeated every 3-4 weeks was used to treat 55 patients with advanced stage III or IV or recurrent disease. Of the 42 fully evaluable patients, there were 3 complete responders (7%) and 10 partial responders (24%). Responses were of short duration (median of 8 months, range 3-15 months) and the median survival of all evaluable patients was only 10 months from the start of therapy. Leukopenia was the major toxicity and was at least moderate in two-thirds of patients. We conclude that the addition of cisplatin and vinblastine to doxorubicin does not improve the clinical utility of doxorubicin in patients with advanced endometrial cancer.

Original languageEnglish (US)
Pages (from-to)193-201
Number of pages9
JournalGynecologic oncology
Volume26
Issue number2
DOIs
StatePublished - Feb 1987

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Alberts, D. S., Mason, N. L., O'Toole, R. V., Hilgers, R. D., Rivkin, S. E., Boutselis, J. G., Pugh, R. P., Vaitkevicius, V. K., Green, J. B., & Oishi, N. (1987). Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: A Southwest Oncology Group study. Gynecologic oncology, 26(2), 193-201. https://doi.org/10.1016/0090-8258(87)90273-3